Pacira awarded Brand Pharmaceuticals agreement with Premier

Pacira BioSciences has been awarded a national group purchasing agreement for Brand Pharmaceuticals with Premier. Effective January 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for EXPAREL. This collaboration is aimed at improving patient care and optimizing cost savings to healthcare organizations and will allow Premier members to access EXPAREL, a single-dose local and regional analgesic that provides prolonged postsurgical pain control while reducing reliance on opioids. “Premier has an impressive network of U.S. hospitals and health systems, and this collaboration provides Pacira an excellent opportunity to expand reach while improving patient safety and care,” said Frank Lee, Chief Executive Officer of Pacira BioSciences. “We are proud to collaborate with organizations like Premier as we continue to advance our mission to provide a non-opioid pain management option to as many patients as possible.”